18,724 Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Boston Trust Walden Corp

Zimmer Biomet logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Boston Trust Walden cut its Zimmer Biomet stake by 3.6%, selling 18,724 shares in the third quarter; it still held 499,389 shares valued at about $44.4 million.
  • Zimmer Biomet’s quarterly results topped estimates, with adjusted EPS of $1.90 and revenue of $2.06 billion, up 3.1% year over year. The company also raised its 2026 outlook, though weak knee sales and margin pressure remain challenges.
  • Analysts were broadly neutral on the stock: 16 rated it Hold, seven Buy and one Sell, with an average price target of $105.68.
  • Five stocks we like better than Zimmer Biomet.

Boston Trust Walden Corp reduced its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 3.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 499,389 shares of the medical equipment provider's stock after selling 18,724 shares during the period. Boston Trust Walden Corp owned about 0.26% of Zimmer Biomet worth $44,361,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp acquired a new stake in shares of Zimmer Biomet in the second quarter valued at $922,000. Hsbc Holdings PLC purchased a new position in Zimmer Biomet in the second quarter valued at $35,417,000. Nykredit A S acquired a new position in Zimmer Biomet during the 2nd quarter worth $3,419,000. Legal & General Group Plc acquired a new position in Zimmer Biomet during the 2nd quarter worth $126,167,000. Finally, Rakuten Investment Management Inc. purchased a new stake in Zimmer Biomet during the 2nd quarter worth about $2,945,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In other news, insider Kevin R. Thornal sold 5,691 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Chad Phipps sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Up 12.8%

Zimmer Biomet stock opened at $109.46 on Thursday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $112.55. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market capitalization of $20.88 billion, a P/E ratio of 26.63, a PEG ratio of 2.33 and a beta of 0.50. The stock has a 50-day simple moving average of $94.90 and a 200-day simple moving average of $91.89.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $0.02. The firm had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2.04 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm's quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.90 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet's dividend payout ratio is presently 23.36%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ZBH shares. Sanford C. Bernstein increased their price target on Zimmer Biomet from $91.00 to $93.00 and gave the company a "market perform" rating in a research report on Thursday, August 6th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research report on Thursday, August 6th. Royal Bank Of Canada upped their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. Zacks Research upgraded shares of Zimmer Biomet from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 25th. Finally, Barclays raised shares of Zimmer Biomet to a "hold" rating in a report on Wednesday, October 7th. Seven investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $105.68.

Read Our Latest Report on ZBH

Key Stories Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.

Further Reading

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zimmer Biomet Right Now?

Before you consider Zimmer Biomet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.

While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines